Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma (MAGNETISMM17)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05462639|
Expanded Access Status : Available
First Posted : July 18, 2022
Last Update Posted : September 11, 2023
|First Submitted Date||June 20, 2022|
|First Posted Date||July 18, 2022|
|Last Update Posted Date||September 11, 2023|
|Brief Title||Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma|
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.
This expanded access protocol will provide access to elranatamab until it becomes commercially available to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option.
Study C1071017 is a single-arm, open-label study in patient with relapsed /refractory multiple myeloma.
Each patient will receive study intervention until disease progression, unacceptable toxicity, withdrawal of consent, study termination or until elranatamab becomes commercially available.
|Study Type||Expanded Access|
|Expanded Access Type||Treatment IND/Protocol|
|Intervention||Drug: Elranatamab (PF-06863135)
BCMA-CD3 bispecific antibody
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Expanded Access Status||Available|
|Listed Location Countries||Canada, United States|
|Removed Location Countries|
|Current Responsible Party||Pfizer|
|Original Responsible Party||Same as current|
|Current Study Sponsor||Pfizer|
|Original Study Sponsor||Same as current|
|Verification Date||September 2023|